期刊
VACCINES
卷 10, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/vaccines10020307
关键词
COVID-19; vaccine; virus-like particle; CuMVTT
资金
- Saiba AG
- Swiss National Science Foundation [310030_185114]
- Swiss National Science Foundation (SNF) [310030_185114] Funding Source: Swiss National Science Foundation (SNF)
Researchers have developed a vaccine candidate that displays the receptor-binding domain (RBD) of SARS-CoV-2 on virus-like particles (VLP), which can induce strong antibody responses and bind to RBDs from other variants. These cross-reactive antibodies are capable of neutralizing different strains of the virus, demonstrating the potential to address emerging variants.
The impact of the COVID-19 pandemic has been reduced since the application of vaccination programs, mostly shown in the reduction of hospitalized patients. However, the emerging variants, in particular Omicron, have caused a steep increase in the number of infections; this increase is, nevertheless, not matched by an increase in hospitalization. Therefore, a vaccine that induces cross-reactive antibodies against most or all variants is a potential solution for the issue of emerging new variants. Here, we present a vaccine candidate which displays receptor-binding domain (RBD) of SARS-CoV-2 on virus-like particles (VLP) that, in mice, not only induce strong antibody responses against RBD but also bind RBDs from other variants of concern (VOCs). The antibodies induced by wild-type (wt) RBD displayed on immunologically optimized Cucumber mosaic virus incorporated tetanus toxin (CuMVTT) VLPs bind to wt as well as RBDs of VOCs with high avidities, indicating induction of strongly cross-reactive IgG antibodies. Interestingly, similar cross-reactive IgA antibodies were induced in immunized mice. Furthermore, these cross-reactive antibodies demonstrated efficacy in neutralizing wt (Wuhan) as well as SARS-CoV-2 VOCs (Beta, Delta, and Gamma). In summary, RBDs displayed on VLPs are capable of inducing protective cross-reactive IgG and IgA antibodies in mice, indicating that it may be possible to cover emerging VOCs with a single vaccine based on wt RBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据